PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Amit Bar-Or, MD, FRCPC / Daniel S. Reich, MD, PhD - Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now Apr 04, 2022

Show notes

Go online to PeerView.com/TCY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in MS discuss the rationale, evidence, and practical potential for BTK inhibitors in patient-centered MS care. Upon completion of this CE activity, participants will be able to: Describe the rationale for inhibiting Bruton’s tyrosine kinase (BTK) to treat multiple sclerosis (MS), Evaluate current evidence related to the efficacy and safety of BTK inhibitors in the treatment of MS, Identify patients who could benefit from treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

John B. Buse, MD, PhD - Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets With GLP-1 RAs Apr 04, 2022

Show notes

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you’ll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Nasser Altorki, MD / Jonathan D. Spicer, MD, PhD, FRCSC - Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes? Apr 04, 2022

Show notes

Go online to PeerView.com/CRA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to the early-stage setting and transforming the multimodal management of resectable stage I-III NSCLC. While remarkable data have emerged from several trials assessing ICIs and rational combinations in neoadjuvant and/or adjuvant settings, many questions remain. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal timing and duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? These and other essential topics are addressed by two leading experts in thoracic surgery in this PeerView Live Seminar and Case Forum. Watch this stimulating discussion of practice-changing data on perioperative immunotherapy, surgical implications and applicability to practice, and how to make the most of ICIs as part of multimodal management of resectable NSCLC to reduce the risk of recurrence and improve cure rates. You will also be able to watch an intriguing debate of real cases selected to highlight the practicalities and challenges of integrating perioperative immunotherapy into practice. Upon completion of this CE activity, participants will be able to: Review the mechanistic aspects of immune checkpoint inhibition, rationale for their use as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapies in these settings, Describe the latest evidence on surrogate endpoints, such as pathologic response criteria, to assess treatment response and gain perspective on the prognosis of patients with resectable lung cancer receiving immunotherapy, Select appropriate resectable NSCLC patients for perioperative immunotherapy, weighing the benefits/limitations and surgical implications based on critical analysis of clinical trial findings and persisting misperceptions, Implement best practices for multidisciplinary communication and collaboration to ensure integration of immunotherapies into multimodal treatment plans for appropriate patients with stage I-III resectable NSCLC.

Purvi S. Parikh, MD, FACP, FACAAI / Cedric ""Jamie"" Rutland, MD - Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma Apr 01, 2022

Show notes

Go online to PeerView.com/FTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma detail the pathophysiology of severe asthma, with a discussion of the underlying mechanisms behind both type 2 and non–type 2 asthma, and novel and emerging therapies for its treatment. Upon completion of this CE activity, participants will be able to: Discuss unmet treatment needs for patients with severe, uncontrolled asthma, particularly those who lack an eosinophilic or allergic phenotype, Explain the role of thymic stromal lymphopoietin (TSLP) as a driver of eosinophilic, allergic, and neutrophilic inflammation as well as structural changes to the airway in asthma due to its position at the top of the inflammatory cascade, Recognize the potential of targeted therapies that block the activity of epithelial cytokines such as TSLP for the treatment of severe, uncontrolled asthma, Identify patients who might be eligible for treatment with novel/emerging biologic therapies that target epithelial cytokines such as TSLP.

Jennifer Wargo, MD, MMSc - Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options Apr 01, 2022

Show notes

Go online to PeerView.com/WUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the practice-changing evidence supporting the use of immunotherapy in resectable melanoma? In this activity, a panel of surgical and medical oncology experts will guide you through these new developments and provide insights on the real-world use of immunotherapy in resectable melanoma, including expanded applications of immunotherapy. The panelists will tackle topics such as the use of checkpoint inhibitors as standard adjuvant therapy in stage III/IV melanoma; the potential of adjuvant immunotherapy in stage II disease; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging novel immune-based treatments in resectable melanoma (eg, LAG-3 inhibitors). This program will help inform the identification of optimal candidates for immunotherapy, address treatment selection and dosing considerations, and support effective management of immune-related events. Upon completion of this CE activity, participants will be able to: Summarize updated evidence and guideline recommendations supporting the use of adjuvant and neoadjuvant immunotherapy in resectable or potentially resectable melanoma, including in stage II, III, and IV settings, Select appropriate adjuvant immunotherapy options for patients with resected melanoma requiring additional treatment, including those with BRAF-mutant and wild-type disease, Integrate neoadjuvant immunotherapy into the management of patients with melanoma who may benefit from presurgical treatment, Manage immune-related adverse events in patients with melanoma receiving immunotherapy in conjunction with surgery.

Stephen V. Liu, MD - Visual Exploration of the Possibilities for Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors Mar 31, 2022

Show notes

Go online to PeerView.com/BNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the expanding role of macrocyclic TKIs in the treatment of fusion-positive NSCLC and other solid tumors. Upon completion of this activity, participants should be better able to: Discuss the structure and mechanisms of action of macrocyclic tyrosine kinase inhibitors (TKIs) and their role in the treatment of fusion-positive non–small cell lung cancer (NSCLC) and other solid tumors, Compare the characteristics, efficacy, and safety of macrocyclic TKIs with those of standard TKIs in the treatment fusion-positive NSCLC and other solid tumors, including in treatment-naïve and pretreated populations, Implement best practices for identifying patients with fusion-positive NSCLC or other solid tumors who might benefit from the use of macrocyclic TKIs in the context of clinical practice or clinical trials.

Robert Dreicer, MD, MS, MACP, FASCO - Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults Mar 30, 2022

Show notes

Go online to PeerView.com/GZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Clinicians who treat patients with prostate cancer have new opportunities to improve outcomes across a variety of settings, but the rapid expansion of treatment options has also presented dilemmas for those trying to choose the right treatment for the right patient. For instance, next-generation anti-androgen agents have proven efficacious in early stages of prostate cancer, while approvals of poly (ADP-ribose) polymerase (PARP) inhibitors are available in later-line metastatic castration-resistant prostate cancer (mCRPC). Combination approaches, under investigation across various stages of prostate cancer, further highlight the expansive opportunities for treatment personalization across the disease continuum. Given this new wealth of options, how do clinicians determine the best treatment course for each patient? Join PeerView and the Prostate Conditions Education Council for an expert-led event designed to answer important questions on prostate cancer treatment in the modern era. Combining insight on relevant data from important trials with practical guidance on using guideline-recommended strategies in clinical practice, this event will help clinicians provide optimal personalized care informed by relevant patient-, tumor-, and treatment-related factors and address AEs related to newer therapies and combinations. Upon completion of this CE activity, participants will be able to: Apply current guideline recommendations for germline and tumor testing for clinically relevant biomarkers in patients with prostate cancer, Integrate novel treatment regimens into the management of patients with advanced prostate cancer, based on recent evidence, genetic/molecular features, current guideline recommendations, and individual patient needs and preferences, Employ evidence- and team-based approaches to proactively mitigate and manage treatment-related AEs that may arise in patients receiving novel therapies and combinations for advanced prostate cancer.

Mark S. Freedman, MD - Leveraging S1PR Modulators to Provide Patient-Centered MS Care: An Expert-Driven Review of the Data Mar 29, 2022

Show notes

Go online to PeerView.com/KAP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.In this expert-led activity, you will learn to leverage S1PR modulators to provide patient-centered MS care Upon completion of this activity, participants should be better able to: Identify the mechanisms of action for S1PR modulators approved for the treatment of multiple sclerosis in the context of disease pathophysiology. Assess the benefits and risks associated with S1PR modulators based on the most recent clinical data,Apply the latest clinical data on S1PR modulators to individualized MS treatment plans

Richard S. Finn, MD - Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape Mar 29, 2022

Show notes

Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each discussion will feature reflective case-centered discussions on the increasingly important role of multidisciplinary treatment across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients! Upon completion of this CE activity, participants will be able to: Evaluate current clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immuno-oncology agents, and novel combination regimens, for patients with advanced HCC, Sequence appropriate therapeutic options across multiple lines of therapy for patients with HCC based on the available evidence, guideline recommendations, and patient-, disease-, and treatment-specific factors, Recommend ongoing clinical trials assessing innovative strategies, including combinations of locoregional therapies with systemic therapies, in HCC patients in different disease and treatment settings, Incorporate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety/tolerability, and patient quality of life, for the optimal assessment and management of patients with HCC across the disease continuum]

Anthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell Cancers Mar 16, 2022

Show notes

Go online to PeerView.com/CZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Covalent BTK inhibitors have transformed the care of B-cell cancers such as CLL/SLL and MCL, but challenges to optimal care remain. How well do you understand the barriers to consistent, efficacious treatment with BTK-based treatment and what that means for treatment planning across multiple lines of therapy? During this activity, experts will tackle these questions and demonstrate how to strategically plan for and implement management protocols that address clinical problems such as BTK inhibitor resistance and intolerance. Throughout, the panelists will share insights on evidence-based and effective sequential therapy (including with second-generation covalent BTK inhibitors, noncovalent BTK options, and non–BTK inhibitor agent classes) and use case-based discussion to illustrate how therapeutic challenges associated with BTK inhibitor therapy can be overcome. Upon completion of this CE activity, participants will be able to: Develop plans to capture therapeutic intolerance or BTK resistance mutations before or at disease progression in patients receiving treatment with covalent BTK inhibitors, Select evidence-based sequential therapy for patients with CLL/SLL or MCL who are progressing on a covalent BTK inhibitor with resistance mutations, Recommend appropriate sequential options for patients with B-cell cancers who exhibit therapeutic intolerance to BTK inhibitors in order to maximize safety, ensure continued efficacy, and augment patient quality of life.